Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FF-10502 |
Synonyms | |
Therapy Description |
FF-10502 is a pyrimidine nucleoside antimetabolite that when converted to the active triphosphosphate form inside cells, inhibits DNA polymerase alpha and beta, potentially resulting in reduced cell proliferation and viability, and inhibition of tumor growth (PMID: 29653962). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FF-10502 | FF-10502-01 | FF-10502 is a pyrimidine nucleoside antimetabolite that when converted to the active triphosphosphate form inside cells, inhibits DNA polymerase alpha and beta, potentially resulting in reduced cell proliferation and viability, and inhibition of tumor growth (PMID: 29653962). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02661542 | Phase Ib/II | FF-10502 | Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas | Completed | USA | 0 |